Abby Hardy, Author at BioTuesdays

Developments

Exicure doses first patient in Phase 2 portion of Merkel cell carcinoma trial

Exicure (NASDAQ:XCUR) dosed the first patient in the Phase 2 dose expansion portion of a clinical trial evaluating cavrotolimod for the treatment of Merkel cell carcinoma. The Phase 2 portion of the ongoing Phase 1b/2...

June 16, 2020

Developments

Titan Pharma launches virtual REMS training for Probuphine health care providers

Titan Pharmaceuticals (NASDAQ:TTNP) launched a fully-virtual Probuphine implant Risk Evaluation and Mitigation Strategy (REMS) training and certification program for qualified health care providers (HCPs) who treat...

June 16, 2020

Feature

Cidara platforms targeting prophylactics and treatments for fungal, viral infections

Cidara Therapeutics (NASDAQ:CDTX) is developing what may be the first antifungal to be approved in 15 years for both the treatment and prevention of invasive fungal disease.

June 16, 2020

Developments

aTyr Pharma doses first patient in Phase 2 COVID-19 trial

aTyr Pharma (NASDAQ:LIFE) dosed the first patient in a Phase 2 study evaluating ATYR1923, an immunomodulator, in COVID-19 patients with severe respiratory complications. The study will enroll 30 COVID-19-positive...

June 15, 2020

Developments

X4 Pharma reports positive Phase 2 mavorixafor data in WHIM syndrome

X4 Pharmaceuticals (NASDAQ:XFOR) reported positive results from its ongoing Phase 2 trial of mavorixafor for WHIM syndrome. WHIM stands for warts; hypogammaglobulinemia, or low antibody levels; infections; and...

June 12, 2020

Developments

Leap Therapeutics DKN-01 gets FDA orphan drug designation for gastric and gastroesophageal junction cancer

The FDA granted Leap Therapeutics’ (NASDAQ:LPTX) DKN-01 orphan drug designation for the treatment of gastric and gastroesophageal junction cancer. DKN-01 is a humanized monoclonal antibody that targets the Dickkopf-1...

June 12, 2020

Developments

Aprea Therapeutics updates Phase 1b/2 eprenetapopt trial results

Aprea Therapeutics (NASDAQ:APRE) reported updated data from its Phase 1b/2 trial evaluating eprenetapopt, in combination with azacytidine, for the treatment of myelodysplastic syndromes (MDS) and acute myeloidleukemia...

June 12, 2020

Developments

IntelGenx pleased with FDA meeting on NDA resubmission for RIZAPORT VersaFilm

IntelGenx (TSXV:IGX; OTCQB:IGXT) obtained clarity on the chemistry, manufacturing and controls information required for the resubmission of its RIZAPORT VersaFilm NDA during its Type A meeting with the FDA on June 10...

June 11, 2020

Executive Moves

Hepion names drug development expert, Dr. Peter Wijngaard, to its board

Peter Wijngaard Hepion Pharmaceuticals (NASDAQ:HEPA) appointed industry veteran, Dr. Peter Wijngaard, to its board of directors. “Dr. Wijngaard provided invaluable guidance to Hepion’s management team during our earlier...

June 10, 2020

Developments

IntelGenx to launch hand sanitizer business

Health Canada has cleared IntelGenx (TSXV:IGX; OTCQB:IGXT) to begin selling its liquid and gel hand sanitizer formulations, which will be produced using excess capacity at the company’s cGMP manufacturing facility in...

June 10, 2020

Author - Abby Hardy

Exicure doses first patient in Phase 2 portion of Merkel cell carcinoma trial

Titan Pharma launches virtual REMS training for Probuphine health care providers

Cidara platforms targeting prophylactics and treatments for fungal, viral infections

aTyr Pharma doses first patient in Phase 2 COVID-19 trial

X4 Pharma reports positive Phase 2 mavorixafor data in WHIM syndrome

Leap Therapeutics DKN-01 gets FDA orphan drug designation for gastric and gastroesophageal junction cancer

Aprea Therapeutics updates Phase 1b/2 eprenetapopt trial results

IntelGenx pleased with FDA meeting on NDA resubmission for RIZAPORT VersaFilm

Hepion names drug development expert, Dr. Peter Wijngaard, to its board

IntelGenx to launch hand sanitizer business

General

More